Agilent's oligonucleotide manufacturing facilities produce high-quality active pharmaceutical ingredient material under current Good Manufacturing Practices (cGMP). Agilent manufactures six commercially approved oligo therapeutics, more than any other oligo CDMO.

We support many clinical siRNA programs and help advance them from early clinical phases through to approved marketed therapies. Agilent is the listed API manufacturer on over 100 INDs including material for Phase I, II, and III clinical studies.

In early 2023, Agilent announced an investment of $725 million to double manufacturing capacity of therapeutic nucleic acids. The addition of two new manufacturing lines will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules.

Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal year 2023 and employs 18,000 people worldwide.